248 related articles for article (PubMed ID: 9737641)
21. Cerivastatin.
McClellan KJ; Wiseman LR; McTavish D
Drugs; 1998 Mar; 55(3):415-20; discussion 421-2. PubMed ID: 9530546
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of ubiquinone concentration and mitochondrial function relative to cerivastatin-induced skeletal myopathy in rats.
Schaefer WH; Lawrence JW; Loughlin AF; Stoffregen DA; Mixson LA; Dean DC; Raab CE; Yu NX; Lankas GR; Frederick CB
Toxicol Appl Pharmacol; 2004 Jan; 194(1):10-23. PubMed ID: 14728975
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of 300 micrograms and 400 micrograms cerivastatin once daily in patients with primary hypercholesterolaemia: a multicentre, randomized, double-blind, placebo-controlled study.
Hanefeld M; Deslypere JP; Ose L; Durrington PN; Farnier M; Schmage N
J Int Med Res; 1999; 27(3):115-29. PubMed ID: 10505301
[TBL] [Abstract][Full Text] [Related]
24. Biopharmaceutical profile of cerivastatin: a novel HMG-CoA reductase inhibitor.
Mück W; Ochmann K; Mazzu A; Lettieri J
J Int Med Res; 1999; 27(3):107-14. PubMed ID: 10505300
[TBL] [Abstract][Full Text] [Related]
25. Influence of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on ubiquinone levels in rat skeletal muscle and heart: relationship to cytotoxicity and inhibitory activity for cholesterol synthesis in human skeletal muscle cells.
Yamazaki H; Suzuki M; Aoki T; Morikawa S; Maejima T; Sato F; Sawanobori K; Kitahara M; Kodama T; Saito Y
J Atheroscler Thromb; 2006 Dec; 13(6):295-307. PubMed ID: 17192694
[TBL] [Abstract][Full Text] [Related]
26. Lack of mutual pharmacokinetic interaction between cerivastatin, a new HMG-CoA reductase inhibitor, and digoxin in healthy normocholesterolemic volunteers.
Weber P; Lettieri JT; Kaiser L; Mazzu AL
Clin Ther; 1999 Sep; 21(9):1563-75. PubMed ID: 10509851
[TBL] [Abstract][Full Text] [Related]
27. Effects of cerivastatin on human arterial smooth muscle cell proliferation and migration in transfilter cocultures.
Axel DI; Riessen R; Runge H; Viebahn R; Karsch KR
J Cardiovasc Pharmacol; 2000 Apr; 35(4):619-29. PubMed ID: 10774794
[TBL] [Abstract][Full Text] [Related]
28. Pharmacodynamics, safety, tolerability, and pharmacokinetics of the 0.8-mg dose of cerivastatin in patients with primary hypercholesterolemia.
Stein E; Isaacsohn J; Stoltz R; Mazzu A; Liu MC; Lane C; Heller AH
Am J Cardiol; 1999 May; 83(10):1433-6. PubMed ID: 10335757
[TBL] [Abstract][Full Text] [Related]
29. Cerivastatin, a New Potent Synthetic HMG Co-A Reductase Inhibitor: Effect of 0.2 mg Daily in Subjects With Primary Hypercholesterolemia.
Stein E; Sprecher D; Allenby KS; Tosiello RL; Whalen E; Ripa SR
J Cardiovasc Pharmacol Ther; 1997 Jan; 2(1):7-16. PubMed ID: 10684437
[TBL] [Abstract][Full Text] [Related]
30. Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same?
Evans M; Rees A
Drug Saf; 2002; 25(9):649-63. PubMed ID: 12137559
[TBL] [Abstract][Full Text] [Related]
31. Toxicity of the HMG-coenzyme A reductase inhibitor, lovastatin, to rabbits.
Kornbrust DJ; MacDonald JS; Peter CP; Duchai DM; Stubbs RJ; Germershausen JI; Alberts AW
J Pharmacol Exp Ther; 1989 Feb; 248(2):498-505. PubMed ID: 2918466
[TBL] [Abstract][Full Text] [Related]
32. Rosuvastatin: characterization of induced myopathy in the rat.
Westwood FR; Scott RC; Marsden AM; Bigley A; Randall K
Toxicol Pathol; 2008 Feb; 36(2):345-52. PubMed ID: 18362199
[TBL] [Abstract][Full Text] [Related]
33. The eye lens evaluation of the atorvastatin-treated white rat.
Zakrzewski P; Milewska J; Czerny K
Ann Univ Mariae Curie Sklodowska Med; 2002; 57(2):165-71. PubMed ID: 12898835
[TBL] [Abstract][Full Text] [Related]
34. Low-dose cerivastatin inhibits spontaneous atherogenesis in heterozygous watanabe hyper lipidemic rabbits.
Pauletto P; Puato M; Faggin E; Sartore S
J Vasc Res; 2000; 37(3):189-94. PubMed ID: 10859477
[TBL] [Abstract][Full Text] [Related]
35. Cerivastatin.
Cheng-Lai A
Heart Dis; 2000; 2(1):93-9. PubMed ID: 11728245
[TBL] [Abstract][Full Text] [Related]
36. Statin-induced muscle necrosis in the rat: distribution, development, and fibre selectivity.
Westwood FR; Bigley A; Randall K; Marsden AM; Scott RC
Toxicol Pathol; 2005; 33(2):246-57. PubMed ID: 15902968
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and drug interactions of the new HMG-CoA reductase inhibitors cerivastatin and atorvastatin in CsA-treated renal transplant recipients.
Renders L; Mayer-Kadner I; Koch C; Schärffe S; Burkhardt K; Veelken R; Schmieder RE; Hauser IA
Nephrol Dial Transplant; 2001 Jan; 16(1):141-6. PubMed ID: 11209008
[TBL] [Abstract][Full Text] [Related]
38. Statin safety: lessons from new drug applications for marketed statins.
Jacobson TA
Am J Cardiol; 2006 Apr; 97(8A):44C-51C. PubMed ID: 16581328
[TBL] [Abstract][Full Text] [Related]
39. Subchronic toxicity of atorvastatin, a hydroxymethylglutaryl-coenzyme A reductase inhibitor, in beagle dogs.
Walsh KM; Albassam MA; Clarke DE
Toxicol Pathol; 1996; 24(4):468-76. PubMed ID: 8864188
[TBL] [Abstract][Full Text] [Related]
40. A 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, cerivastatin, suppresses production of matrix metalloproteinase-9 in human abdominal aortic aneurysm wall.
Nagashima H; Aoka Y; Sakomura Y; Sakuta A; Aomi S; Ishizuka N; Hagiwara N; Kawana M; Kasanuki H
J Vasc Surg; 2002 Jul; 36(1):158-63. PubMed ID: 12096274
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
